FDA calls out Alar Pharmaceuticals for promoting unapproved ketamine drug at APA meeting

The FDA has publicly reprimanded Alar Pharmaceuticals for promoting an unapproved ketamine-based drug at the American Psychiatric Association meeting, highlighting regulatory non-compliance risks in drug marketing.

This Wire brief sits within Fusion42's coverage of Biotech.